THERAPY DOSSIER · th-8b3dd8207217

Candesartan and telmisartan

Drug · Type-1 angiotensin II receptor (AT1) antagonist

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Type-1 angiotensin II receptor (AT1) antagonist
Target: Type-1 angiotensin II receptor (AGTR1)
Injury models: TBI · Ischaemia-reperfusion
Reported indication: Not recorded
First approval: 1998
Development stage: Not recorded
ChEMBL record: CHEMBL1014 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Candesartan cilexetil; Atacand; Amias; Blopress; TCV-116
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00360763 ↗PHASE4unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

Enrolment: 600 · Results not recorded

NCT05637853 ↗PHASE4active not recruiting

Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Enrolment: 60 · Results not recorded

NCT03847506 ↗PHASE4completed

Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

Hypertension, Hyperlipidemia

Enrolment: 127 · Results not recorded

NCT02521246 ↗PHASE3withdrawn

Efficacy and Safety of Fixed Dose Candesartan Cilexetil + Chlorthalidone Compared With HYZAAR in Hypertension Control

Essential Arterial Hypertension

Enrolment: 0 · Results not recorded

NCT02047019 ↗PHASE3withdrawn

A Study of Nifedipine GITS and Candesartan Cilexetil in Combination in Adults With Essential Hypertension Inadequately Controlled on 16 mg Candesartan Monotherapy

Hypertension

Enrolment: 0 · Results not recorded

NCT00699452 ↗PHASE3unknown

The Potential of Candesartan to Retard the Progression of Aortic Stenosis

Aortic Valve Stenosis

Enrolment: 120 · Results not recorded

NCT02166697 ↗NAcompleted

Candesartan Cilexetil Tablets Specified Drug-use Survey: Hypertension Survey on Patients With Metabolic Syndrome

Hypertension

Enrolment: 14151 · Results not recorded

NCT03460327 ↗NArecruiting

Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan

Obesity, Morbid

Enrolment: 12 · Results not recorded

NCT02211638 ↗NAcompleted

Blopress Tablets Special Drug Use Surveillance (Challenge - Quality Control)

Hypertension

Enrolment: 18113 · Results not recorded

NCT04138316 ↗NAcompleted

CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability Observational Study

Migraine · Head Pain

Enrolment: 85 · Results not recorded

Preclinical evidence 2

2 studies reported at therapy level; 2 evidence entries itemised.

PMID 26115674 ↗2015Reported benefit

Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.

MouseTBIControlled cortical impactDoses that did not affect blood pressure (numerical values…Therapeutic window up to 6 h after injury

Model: Controlled cortical impact

Both candesartan and telmisartan reduced lesion volume, neuronal injury and apoptosis, astrogliosis, microglial activation and pro-inflammatory signalling and preserved cerebral blood flow, with a therapeutic window up to 6 h; cognitive impairment at 30 days was ameliorated only by candesartan, and…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

PMID 25326022 ↗2014Reported benefit

Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMalen = Three main groups with 32 rats per group; experiments perfo…Intravenous0.1 mg/kg (non-hypotensive dose)One hour before induction of ischaemia

Model: Transient focal cerebral ischaemia by intraluminal middle cerebral artery occlusion with a 3-0 nylon filament for 60 min followed by 24 h reperfusion

A single non-hypotensive intravenous dose of candesartan one hour before middle cerebral artery occlusion improved neurological scores and reduced infarct volume by 54.9 per cent, oedema by 59.2 per cent and Evans blue extravasation by 54.9 per cent without altering arterial blood pressure.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

Loading the evidence…